Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation

In a report released on April 2, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The compa...

RBC Capital Reaffirms Their Buy Rating on Insulet (PODD)

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), closed 1.50% higher in Thursday’s trading following news that Iran and Oman ...

Vanguard S&P 500 ETF (VOO) Daily Update, 4/3/2026?

The SPDR S&P 500 ETF Trust ($SPY) gained 0.09% today, April 2, marking a continued rally driven primarily by hopes of de-escalation in the Iran con...

Why Is the SPY ETF Up Today, 4/2/2026?

Escalating tensions in the Middle East, a spike in crude prices, and signs of fatigue in the U.S. labor market are fueling fresh analyst chatter ab...

Bracing for Stagflation? These 2 Stocks Offer Mouth-Watering Upside

A combination of the conflict in the Middle East, soaring oil prices, and a weaker U.S. job market has led to rising warnings from analysts about t...

Stagflation Watch: 3 Stocks Analysts Are Backing (PODD vs. CEG vs. WMT)

Piper Sandler Remains a Buy on Insulet (PODD)

Insulet ( ($PODD) ) has provided an announcement. On March 12, 2026, Insulet initiated a voluntary medical device correction in the U.S. for specif...

Current Quarter	$1.14	Next Quarter	$1.37
Current Year	$6.16	Next Year	$7.83
QoQ Growth	+20.2%	YoY Growth	+27.1%
3Y EPS CAGR	+1.9%	Target Price	$355.17
Consensus	Buy	Upside	+73.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PODD	$204.31	0.00%	886.80K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PODD	$204.31	0%	886.80K
3
4
5
6

PODD

PODD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Insulet Corporation Data in Excel

Get Insulet Corporation Data in Excel